Studies on the Effects of Postoperative Immunochemotherapy for Gastric Cancer

Inaba, Syunzo; Yagawa, Hirokazu; Katšube, Takao; Ogawa, Tomoko; Isikawa, Sinya; Ohtani, Yoichi; Ogawa, Kenji; Kajiwara, Tetsuro

doi:10.3919/ringe1963.50.1112

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that immunochemotherapy may be effective in more advanced cancer, which is associated with a large residual tumor volume and extremely high immunological risks. There are, however, reports that the therapy was effective in stage I and stage II lung cancer (Okayasu et al 1989), only stage in II cervical cancer (Noda et al 1989), and only in curatively resected stage i and N stomach cancer but not in noncuratively resected lesions (Inaba et al 1989). Causes of this discrepancy include differences in immunological environment of cancers of individual organs and differences in concomitant treatments.…”

Section: Disucussionmentioning

confidence: 99%

Long-Term Results of Immunochemotherapy for Advanced Ovarian Cancer.

et al. 1991

View full text Add to dashboard Cite

between January 1982 and October 1985. They were assigned postoperatively by randomized trials to immunochemotherapy or chemotherapy alone. Of all 51 patients, long-term results of immunochemotherapy for 43 patients were evaluated versus radicality of initial cytoreductive surgery. As a result, the group of patients treated with immunochemotherapy tended to have a better prognosis than the group of patients treated with chemotherapy alone, whereas no statistical difference was observed between the two groups. Moreover, no significant difference was observed in the monitoring of OKT 4/8 ratio between the two groups. However, immunochemotherapy produced a favorable prognosis in the patients with residual disease of greater than 2cm in diameter at initial surgery. In conclusion, these data suggested that immunochemotherapy may have some impact on survival of patients with ovarian adenocarcinoma.

show abstract

Section: Disucussionmentioning

confidence: 99%